ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Ten Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients

S. El Hajj, J. Azzi, M. Kim, S. Gabardi.

Pharmacy, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Kidney Transplant, Brigham and Women's Hospital, Boston
Kidney Transplant, Brigham and Women's Hospital, Boston.

Meeting: 2018 American Transplant Congress

Abstract number: D168

Keywords: Cytomeglovirus

Session Information

Date: Tuesday, June 5, 2018

Session Name: Poster Session D: Kidney Infectious

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Related Abstracts
  • Eight Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients.
  • Standard Dose Valganciclovir Prophylaxis for High-Risk Kidney Transplant Recipients Reduces Incidences of Breakthrough and Resistant Cytomegalovirus Infection.

Introduction: Cytomegalovirus (CMV) remains one the most clinically relevant and frequent post-transplant infections. Despite the availability of effective antiviral drugs, CMV continues to be of major clinical concern in transplant populations. Valganciclovir (VGCV) dose and duration for prophylaxis differs among institutions, and may be based on experience and consensus rather than clinical trials. The purpose of this analysis is to assess the prevalence and determine the risk factors of CMV viremia and disease in renal transplant recipients (RTR) at risk of CMV, using low-dose VGCV for 6 months.

Methods: A retrospective cohort study was conducted on adult RTR between January 1, 2006, and December 31, 2015 using electronic medical records. Patients were included if they were aged 18 years or older, were followed at our institution for at least one year after transplant, and were at risk for CMV (D+/R+, D+/R-, D-/R+). CMV D-/R- patients were excluded. The primary objective was to evaluate the incidence of CMV viremia, CMV disease, breakthrough, and resistance at one year post-transplant.

Results: A total of 647 RTR charts were reviewed. Of those, 401 patients were included in the study (46.4% D+/R+, 26.8%, D-/R+ and 26.8% D+/R-). Within the first year of transplant, 47 patients (11.7%) developed CMV viremia within 12 months post-transplant. Of those, 26 patients (55.3%) experienced asymptomatic viremia, and 21 (44.7%) had CMV disease, viral syndrome or tissue-invasive. The incidence of breakthrough was 2.5% and ganciclovir-resistance 1.7%. Early discontinuation of VGCV occurred in 72 patients (18%), mainly due to leukopenia (93.2%). A multiregression analysis revealed that D+/R- population had a 13.25 times higher risk of developing CMV disease (p=0.001),and patients who experienced AMR had 6 times higher risk of developing CMV disease (p=0.006). Ganciclovir-resistance was associated with D+/R- status, presence of BK, AMR and concomitant OI (p= 0.043, p=0.01, and p=0.035, respectively). In addition, breakthrough CMV was significantly related to ganciclovir-resistance (p=0.006)

Conclusion: Alow-dose VGCV regimen provides low rate of viremia, and viral disease in RTR. High risk population (D+/R-), and presence of AMR were highly associated with CMV incidence.

CITATION INFORMATION: El Hajj S., Azzi J., Kim M., Gabardi S. Ten Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Hajj SEl, Azzi J, Kim M, Gabardi S. Ten Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients [abstract]. https://atcmeetingabstracts.com/abstract/ten-years-of-low-dose-valganciclovir-evaluating-the-incidence-and-risk-factors-of-cmv-in-kidney-transplant-recipients/. Accessed March 8, 2021.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.